Prihlásiť sa Zaregistrujte sa zadarmo

Hrubá marža spoločnosti NeuroVive Pharmaceutical AB

Aká je hodnota metriky Hrubá marža spoločnosti NeuroVive Pharmaceutical AB?

Hodnota metriky Hrubá marža spoločnosti NeuroVive Pharmaceutical AB je -68,572.19%

Aká je definícia metriky Hrubá marža?



Hrubá marža (Gross margin) je rozdiel medzi príjmami a nákladmi na predaný tovar vydelený príjmami a vyjadrený v percentách.

Gross margin is a type of profit margin, specifically a form of profit divided by net revenue. It is generally calculated as the selling price of an item, minus the cost of goods sold (production or acquisition costs, not including indirect fixed costs like rent, or administrative costs). The purpose of margins is to give a description of the gross profit.

Hrubá marža spoločností v sektore Miscellaneous sektor na LSE v porovnaní so spoločnosťou NeuroVive Pharmaceutical AB

Čomu sa venuje spoločnosť NeuroVive Pharmaceutical AB?

Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.

Firmy s metrikou hrubá marža podobnou spoločnosti NeuroVive Pharmaceutical AB